News | October 02, 2013

New Molecular Imaging Agents Being Developed for Fluorescence-Guided Brain Cancer Surgery

Dartmouth, LI-COR and Affibody receive NIH grant for development and translation of imaging agents for fluorescence-guided surgery

nuclear imaging clinical trial study radiopharmaceuticals tracers li-cor

October 2, 2013 —The Thayer School of Engineering and Geisel School of Medicine at Dartmouth together with LI-COR Biosciences and Affibody AB announced a new partnership to establish an efficient pipeline for development and translation of molecularly targeted agents. The National Cancer Institute funds the five-year project.

The study will use a cost-effective, risk-diluted approach for rapid development and testing of molecularly-targeted imaging agents in phase 0 microdosing studies. The microdosing studies are designed to evaluate imaging of specific targets.

“Targeting an evaluation of imaging in early human surgical trials will allow us to efficiently assess potential candidates for further development,” said Brian Pogue, Ph.D., lead investigator and Dartmouth professor. “This approach will dramatically accelerate the paradigm shift to molecularly guided surgical oncology. This grant will allow us to develop and test agents produced with current Good Manufacturing Practices whose primary use will be in diagnostic guidance in surgical oncology, and used at microdoses similar to nuclear medicine tracers.”

The first agent will be an Affibody molecule targeted to the epidermal growth factor receptor (EGFR), which is overexpressed in a broad range of cancers.

Fredrik Frejd, Ph.D., chief science officer, Affibody. “Due to the high target specificity and favorable tissue distribution properties of Affibody molecules, tumors and their boundaries can be rapidly identified and characterized, which may allow for the development of image-guided surgery as a potential option for improved brain tumor treatment.”

The study will employ commercially available state-of-the-art surgical microscopes from Leica and Zeiss that are equipped for intraoperative fluorescence imaging. Surgical signal detection and binding specificity will be the primary outcomes from the phase 0 trials. First-in-human studies with recurrent high-grade brain tumor patients will be pursued at Dartmouth. Approval for the microdosing studies will be sought under the exploratory investigational new drug (IND) pathway at the FDA.

For more information: www.licor.com

Related Content

New Studies Highlight MRI Use for Prostate Cancer Screening and Management
News | Magnetic Resonance Imaging (MRI) | May 21, 2018
Three new studies presented at the 113th annual meeting of the American Urological Association (AUA) highlight the...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
Breast Cancer Places Greater Financial Burden on Black Women
News | Women's Health | May 16, 2018
Having breast cancer placed a significantly greater financial strain on black women than white women, according to a...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Impaired Brain Pathways May Cause Attention Problems After Stroke
News | Neuro Imaging | May 10, 2018
Damage to some of the pathways that carry information throughout the brain may be responsible for attention deficit in...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Pilot Study Initiated for Blood-Based Breast Test
News | Oncology Diagnostics | May 01, 2018
Overlake Medical Center in Bellevue, Wash., announced it has enrolled 85 patients in a pilot study of a blood test to...
Computers Equal Radiologists in Assessing Breast Density and Associated Breast Cancer Risk
News | Breast Density | May 01, 2018
Automated breast density evaluation was just as accurate in predicting women’s risk of breast cancer, found and not...
Overlay Init